All Things Angioedema – Learning about angioedema with Dr. Thomas Buttgereit
Cholinergic Urticaria & Angioedema: What You Need to Know
10 Jun 2025
In this episode, Thomas welcomes Dr. Sabine Altrichter, urticaria expert and physician at Kepler University Hospital in Linz, Austria, to discuss a fascinating and underrecognized condition: cholinergic urticaria — especially in patients who also experience angioedema.They discuss:🔹 What makes cholinergic urticaria different from other urticaria types? 🔹 Why do some patients develop angioedema in addition to wheals?🔹 How can we distinguish between cholinergic urticaria and exercise-induced anaphylaxis?🔹 What are current and emerging treatment options? Dr. Altrichter shares insights from clinical research and experience, including findings that show nearly half of cholinergic urticaria patients may develop angioedema.She explains the two main subtypes — allergy-related and sweat gland-related — and what this means for diagnosis and treatment. The discussion also covers new treatment options like anti-IgE therapies, mast cell-depleting agents, and drugs in the clinical pipeline like remibrutinib. Join us for a practical and engaging conversation on how to better diagnose and manage this unique condition.Key Learnings from the Episode:Cholinergic urticaria is triggered by body heating (e.g., exercise, sauna, passive warmth), leading to small, itchy wheals. Nearly 50% of patients also experience angioedema, often around the eyes or lips, indicating more severe disease.Patients with angioedema tend to have longer-lasting and more intense symptoms than those without. Two subtypes are emerging: one IgE/allergy-related and another with sweat gland dysfunction. Angioedema in cholinergic urticaria is not typically life-threatening, but may be accompanied by mild systemic symptoms. Provocation testing (e.g., exercise or stair running) helps confirm diagnosis. Antihistamines are first-line, but often insufficient in patients with angioedema. Omalizumab (anti-IgE) is effective in about two-thirds of patients. Mast cell-depleting therapies and remibrutinib are promising treatments in development. Differentiating from exercise-induced anaphylaxis is key: the latter causes more unpredictable and systemic reactions.Ongoing trials may reshape how we treat both mild and severe forms of the disease. Chapters 00:00 Introduction to Chronic Inducible Urticaria 03:03 Understanding Cholinergic Urticaria 04:57 Angioedema and Its Connection to Cholinergic Urticaria 07:23 Subtypes of Cholinergic Urticaria 08:17 Mechanisms Behind Cholinergic Urticaria 09:56 Diagnosis of Cholinergic Urticaria 11:17 Treatment Options for Cholinergic Urticaria 13:10 Differentiating from Exercise-Induced Anaphylaxis 14:34 Future Treatments and Research 16:41 Mast Cell Depletion and Its Implications Do you have suggestions for future episodes? Please provide feedback and offer your suggestions for future topics and expert selection here.Feedback form ATA: https://forms.office.com/e/ZWxx3D4Cmr
No persons identified in this episode.
This episode hasn't been transcribed yet
Help us prioritize this episode for transcription by upvoting it.
Popular episodes get transcribed faster
Other recent transcribed episodes
Transcribed and ready to explore now
SpaceX Said to Pursue 2026 IPO
10 Dec 2025
Bloomberg Tech
Don’t Call It a Comeback
10 Dec 2025
Motley Fool Money
Japan Claims AGI, Pentagon Adopts Gemini, and MIT Designs New Medicines
10 Dec 2025
The Daily AI Show
Eric Larsen on the emergence and potential of AI in healthcare
10 Dec 2025
McKinsey on Healthcare
What it will take for AI to scale (energy, compute, talent)
10 Dec 2025
Azeem Azhar's Exponential View
Reducing Burnout and Boosting Revenue in ASCs
10 Dec 2025
Becker’s Healthcare -- Spine and Orthopedic Podcast